. 2019 Sep 30;37(3):215–223. doi: 10.3857/roj.2019.00332

Table 2.

Univariate analysis of prognostic factors for 5-year survivals

Variable	No. of patients	BCFFS		CFFS		DMFS
Variable	No. of patients	%	p-value	%	p-value	%	p-value
Age (yr)			0.517		0.669		0.236
≤67	82	77.3		92.0		92.0
>67	86	79.1		96.3		97.6
Initial PSA (ng/mL)			0.102		0.069		0.218
≤10	52	86.7		95.9		98.0
10–20	53	78.3		98.1		98.1
>20	63	71.2		89.8		89.8
Gleason score			0.046		0.045		0.032
≤7	82	87.6		98.8		98.8
8–10	82	68.6		90.7		92.2
pT stage			0.073		0.231		0.227
1–2	54	82.8		97.9		100
3a	65	82.0		96.0		96.0
3b–T4	46	68.1		88.9		88.9
pN stage			0.010		0.060		0.353
0	159	80.4		94.9		95.7
1	9	37.5		80.0		80.0
Resection margin			0.468		0.366		0.149
Negative	89	78.8		96.4		97.7
Positive	79	78.4		91.5		91.5
PNI			0.478		0.927		0.829
No	39	88.6		93.8		93.8
Yes	129	74.9		94.6		95.5
LVI			0.300		0.001		<0.001
No	143	79.8		96.6		97.4
Yes	25	71.1		79.5		79.5
PSA at PORT (ng/mL)			<0.001		<0.001		<0.001
≤0.2	73	96.6		97.8		97.8
>0.2 and ≤0.5	33	83.2		100		100
>0.5 and ≤1.0	24	78.4		100		100
>1.0	38	37.0		78.7		81.8
Treatment aim			0.001		0.222		0.300
Adjuvant	48	97.0		96.8		96.8
Salvage	120	70.8		93.3		94.3
EQD_2/2 (Gy)			0.569				0.214
<69.3	82	74.3		97.3	0.254	97.3
≥69.3	86	80.4		92.3	0.182	93.6
RT volume			0.254				0.265
Surgical bed	46	88.6		96.2		96.2
Whole pelvis	122	74.4		93.5		94.5
RT method			0.007		0.265		0.306
IMRT	121	81.2		93.1		94.2
3D-CRT	24	59.8		91.7		91.7
Combination	23	89.5		100		100
NA-ADT			0.231		0.009		0.018
No	113	79.2		97.3		97.3
Yes	55	76.9		87.2		89.6
CA-ADT			<0.001		0.037		0.187
No or unknown	41	39.4		86.6		86.6
Yes	127	89.2		96.6		97.5

BCFFS, biochemical failure-free survival; CFFS, clinical failure-free survival; DMFS, distant metastasis-free survival; PSA, prostatespecific antigen; PNI, perineural invasion; LVI, lymphovascular invasion; PORT, postoperative radiotherapy; EQD_2/2, equivalent dose in 2 Gy fractions at α/β ratio of 2.0; RT, radiotherapy; IMRT, intensity-modulated radiotherapy; 3D-CRT, three-dimensional conformal radiotherapy; NA-ADT, neoadjuvant androgen deprivation therapy before PORT; CA-ADT, concurrent or adjuvant androgen deprivation therapy with PORT.